We are live on !
Find out more
FT Options Portfolio holdings
AUM
$66.4M
Turnover
60.61%
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
(+14%)
Cap. Flow
+$2.99M
Cap. Flow % of AUM
Cap. Flow %
4.5%
Top 10 Holdings %
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72
Avg Time Held
Equity + Options
0.5
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.1
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Incyte
INCY
|
+$3.53M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$2.94M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$2.18M |
| 4 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$1.54M |
| 5 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$1.37M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
General Mills
GIS
|
+$2.52M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$2.31M |
| 3 |
Amgen
AMGN
|
+$2.08M |
| 4 |
Abbott
ABT
|
+$1.72M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$1.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.45% |
| 2 | Miscellaneous | 41.8% |
| 3 | Consumer Discretionary | 7.1% |
| 4 | Consumer Staples | 6.25% |
| 5 | Communication Services | 0.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
PUT
DELISTED
Dermira, Inc.
DERM
| $94K | 0.14% |
+10,000
| New | +$262K |
2017 Q3
0 quarters
|
|
102
CALL
Cytokinetics
CYTK
$8.8B
| $93K | 0.14% |
+31,100
| New | +$425K |
2017 Q3
0 quarters
|
|
103
CALL
Gilead Sciences
GILD
$190B
| $92K | 0.14% |
+60,000
| New | +$4.59M |
2017 Q3
0 quarters
|
|
104
CALL
Ionis Pharmaceuticals
IONS
$7.45B
| $90K | 0.14% |
+84,000
| New | +$4.4M |
2017 Q3
0 quarters
|
|
105
Larimar Therapeutics
LRMR
$258M
| $90K | 0.14% |
2,138
-2,951
| -58% | -$123K |
2015 Q4
7 quarters
|
|
|
SVVC
106
DELISTED
Firsthand Technology Value Fund, Inc. Common Stock
SVVC
| $88K | 0.13% |
11,000
-9,000
| -45% | -$70.5K |
2016 Q1
6 quarters
|
|
107
PUT
iShares Biotechnology ETF
IBB
$11B
| $86K | 0.13% |
88,500
+19,500
| +28% | +$2.08M |
2017 Q1
2 quarters
|
|
|
AIMT
108
CALL
DELISTED
Aimmune Therapeutics
AIMT
| $84K | 0.13% |
+70,000
| New | +$1.51M |
2017 Q3
0 quarters
|
|
|
ZYNE
109
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $82K | 0.12% |
45,000
+42,000
| +1,400% | +$444K |
2017 Q2
1 quarter
|
|
|
TTPH
110
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $82K | 0.12% |
+600
| New | +$80.3K |
2017 Q3
0 quarters
|
|
111
Hain Celestial
HAIN
$19.3M
| $74K | 0.11% |
1,800
-8,200
| -82% | -$339K |
2017 Q1
2 quarters
|
|
112
CALL
Hershey
HSY
$33.9B
| $74K | 0.11% |
73,000
+16,000
| +28% | +$1.7M |
2016 Q1
6 quarters
|
|
|
PRTK
113
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $69K | 0.1% |
+2,748
| New | +$64K |
2017 Q3
0 quarters
|
|
114
PUT
Colgate-Palmolive
CL
$74.8B
| $67K | 0.1% |
28,500
-5,000
| -15% | -$360K |
2016 Q2
5 quarters
|
|
|
115
Colgate-Palmolive
CL
$74.8B
| $66K | 0.1% |
900
-12,847
| -93% | -$926K |
2017 Q2
1 quarter
|
|
|
MON
116
CALL
DELISTED
Monsanto Co
MON
| $65K | 0.1% |
21,400
-3,000
| -12% | -$353K |
2016 Q1
6 quarters
|
|
117
CALL
Kohl's
KSS
$2.54B
| $60K | 0.09% |
+17,500
| New | +$717K |
2017 Q3
0 quarters
|
|
|
LJPC
118
PUT
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $55K | 0.08% |
+38,000
| New | +$1.22M |
2017 Q3
0 quarters
|
|
119
CALL
AbbVie
ABBV
$500B
| $53K | 0.08% |
30,000
+20,000
| +200% | +$1.52M |
2016 Q1
6 quarters
|
|
120
PUT
Sarepta Therapeutics
SRPT
$1.96B
| $51K | 0.08% |
55,500
+35,500
| +178% | +$1.42M |
2017 Q2
1 quarter
|
|
|
FCSC
121
PUT
DELISTED
Fibrocell Science Inc.
FCSC
| $51K | 0.08% |
+24,120
| New | +$390K |
2017 Q3
0 quarters
|
|
|
ZSAN
122
DELISTED
Zosano Pharma Corporation
ZSAN
| $49K | 0.07% |
86
| – | – |
2017 Q1
2 quarters
|
|
123
PUT
Bristol-Myers Squibb
BMY
$124B
| $48K | 0.07% |
60,100
+30,300
| +102% | +$1.77M |
2017 Q1
2 quarters
|
|
|
124
PUT
Ionis Pharmaceuticals
IONS
$7.45B
| $48K | 0.07% |
+20,300
| New | +$1.06M |
2017 Q3
0 quarters
|
|
|
ONCE
125
PUT
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $48K | 0.07% |
+8,900
| New | +$676K |
2017 Q3
0 quarters
|
|
Similar funds
FIM
MKCM
MFM
VE
FT Options's Q3 2017 Portfolio in Review
As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
FT Options deployed $2.99M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 43% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.
On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.
- FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
- FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
- FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
- FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
- FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
- FT Options opened 108 new positions and closed 72 in Q3 2017.
- FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.
Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.